Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Spire Healthcare following FY24 results

(Sharecast News) - Analysts at Berenberg lowered their target price on Spire Healthcare from 300.0p to 255.0p on Friday after the firm reported weaker-than-expected, missing consensus expectations across revenues, as well as adjusted underlying earnings and adjusted EPS. Berenberg noted that Spire's shares were "meaningfully down" on the day as its FY25 guidance implied material cuts to consensus EBITDA and earnings estimates due to the unfavourable impact from higher National Insurance costs, the increase in the UK National Minimum Wage, an unfavourable payor mix and higher energy costs.

In response to these headwinds, Spire stated that it was focused on ramping up its cost-saving initiatives, with new targets of £30.0m in FY25 and £80.0m of cumulative cost savings over FY24-FY26. It plans to achieve this by using electronic procurement, better staff management and by centralising patient support centres.

"We make 1-2% cuts to our revenue forecasts and 8-12% cuts to our EBIT estimates as we factor in the unfavourable impact from cost headwinds (partially offset by internal efficiency measures). We make material cuts to our earnings estimates as we factor in higher finance costs (£103.0m) and taxes (above 30% tax rate) from FY25," said the German bank, which noted that execution would be key to Spire's shares rerating.

In FY25, Berenberg expects bank leverage to be maintained at roughly 2x and free cash flow to remain positive.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.